Highlights NewAmsterdam Pharma Company N.V. Börse Stuttgart

Equities

KH6

NL00150012L7

Real-time Estimate Tradegate Other stock markets 11:01:06 2024-07-17 am EDT			5-day change	1st Jan Change
17.35 ^EUR	+0.87%		-4.44%	+73.74%

Jul. 08	NewAmsterdam Pharma Completes Enrollment for Phase 3 Trial of Potential Cardiovascular Disease Treatment	MT
Jul. 08	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NewAmsterdam Pharma Completes Enrollment for Phase 3 Trial of Potential Cardiovascular Disease Treatment	Jul. 08	MT
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors	Jul. 08	CI
NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	Jun. 11	MT
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings	May. 21	CI
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	May. 09	MT
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	Apr. 09	CI
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd	Mar. 12	CI
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops	Feb. 28	MT
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Newamsterdam Pharma Company N.V. Announces Initial Data from Phase 2A Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an Apoe4 Mutation	23-09-21	CI
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-07	CI
NewAmsterdam Pharma Company N.V. Provides Clinical Development Updates	23-08-07	CI
Newamsterdam Pharma Company N.V. Completes Enrollment in Pivotal Phase 3 Broadway Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia And/Or Established Atherosclerotic Cardiovascular Disease	23-07-25	CI
NewAmsterdam Pharma Company N.V. Announces Positive Topline Results from Phase 2B Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients	23-06-05	CI
NewAmsterdam Pharma Company N.V. Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023	23-06-03	CI
NewAmsterdam Pharma Company N.V. Provides Clinical Development Updates	23-05-08	CI
NewAmsterdam Pharma Completes Enrollment in Phase 3 Trial of Obicetrapib to Treat Heterozygous Familial Hypercholesterolemia	23-04-24	MT
Newamsterdam Pharma Completes Enrollment in Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia	23-04-24	CI
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NewAmsterdam Pharma Company N.V. Börse Stuttgart

Equities

KH6

NL00150012L7

Highlights

Filters